![](/img/cover-not-exists.png)
PS04.02 Randomized, Double-Blind Study of Erlotinib Plus Ramucirumab or Placebo in First Line for Patients with EGFR Mutation-Positive Metastatic NSCLC
Polit, R.R., Reck, M., Juan Vidal, O., Nadal, E., Lee, P., Alexandris, E., He, S., Nakagawa, K., Garon, E.B.Volume:
12
Language:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2017.09.071
Date:
November, 2017
File:
PDF, 236 KB
english, 2017